Utama › Kanser Payudara Triple-Negatif › Michigan › Grand Rapids
Kajian klinikal Kanser Payudara Triple-Negatif di Grand Rapids, MI
15 kajian untuk Kanser Payudara Triple-Negatif sedang mencari peserta di lokasi dalam dan sekitar Grand Rapids (dalam lingkungan kira-kira 30 batu). Buka kajian untuk melihat siapa yang layak menyertai dan cara menghubungi pasukan kajian.
Teks kajian rasmi (Bahasa Inggeris)
Mengambil peserta untuk kajian di sini? Paparkan di bahagian atas halaman ini — $99 selama 30 hari →
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
Mengambil pesertaFasa 1
- South Texas Accelerated Research Therapeutics (START), Grand Rapids
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Mengambil pesertaFasa 1
- START Midwest Cancer and Hematology Centers of W Michigan, Grand Rapids
177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
Mengambil pesertaFasa 1/2
- BAMF Health, Grand Rapids
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
Mengambil pesertaFasa 3
- Cancer & Hematology Centers of Western Michigan ( Site 0026), Grand Rapids
A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors
Mengambil pesertaFasa 1
- BAMF Health, Grand Rapids
Phase 1 Study of a Self-amplifying RNA Vaccine (ITI-5000) in Stage 2-3 Triple Negative Breast Cancer
Mengambil pesertaFasa 1
- START Midwest, Grand Rapids
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
Mengambil pesertaFasa 3
- Cancer and Hematology Centers of Western Michigan, Grand Rapids
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
Mengambil pesertaFasa 1
- South Texas Accelerated Research Therapeutics (START) Midwest, Grand Rapids
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
Mengambil pesertaFasa 1
- South Texas Accelerated Research Therapeutics (START) Midwest, Grand Rapids
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
Mengambil pesertaFasa 1/2
- Research Site, Grand Rapids
Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
Mengambil pesertaFasa 1/2
- START Midwest, Grand Rapids
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Mengambil pesertaFasa 1/2
- START Midwest, Grand Rapids
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
Mengambil pesertaFasa 1
- BAMF Health, Grand Rapids
A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors
Mengambil pesertaFasa 1
- START Midwest, LLC, Grand Rapids
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
Mengambil pesertaFasa 1
- START Midwest /ID# 248685, Grand Rapids
Kajian Kanser Payudara Triple-Negatif di bandar lain
- Houston, TX42 kajian
- New York City, NY31 kajian
- Nashville, TN28 kajian
- Los Angeles, CA27 kajian
- Boston, MA26 kajian
- San Antonio, TX23 kajian
- St. Louis, MO21 kajian
- Arlington, VA20 kajian
- Atlanta, GA20 kajian
- Dallas, TX18 kajian
- Chicago, IL16 kajian
- Columbus, OH16 kajian
Kajian lain di Grand Rapids
- Kanser Paru-paru Bukan Sel Kecil44 kajian
- Kanser Kolorektal40 kajian
- Kanser (semua jenis)28 kajian
- Kanser Payudara26 kajian
- Kanser Ovari24 kajian
- Kanser Metastatik22 kajian
- Kanser Prostat19 kajian
- Kanser Endometrium18 kajian
- Kanser Perut18 kajian
- Kanser Pankreas18 kajian
- Melanoma17 kajian
- Karsinoma Sel Skuamosa Kepala dan Leher15 kajian
Daripada ClinicalTrials.gov, data diperoleh pada 6 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.